{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:47:41Z","timestamp":1767649661965},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/gme.0b013e318212499c","type":"journal-article","created":{"date-parts":[[2011,3,24]],"date-time":"2011-03-24T05:59:43Z","timestamp":1300946383000},"page":"459-467","source":"Crossref","is-referenced-by-count":30,"title":["Pharmacological therapy for abnormal uterine bleeding"],"prefix":"10.1097","volume":"18","author":[{"given":"JoAnn V.","family":"Pinkerton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"1","key":"R1-21-20210211","first-page":"CD001016","article-title":"Cyclical progestogens for heavy menstrual bleeding.","author":"Lethaby","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R2-21-20210211","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00002018-200831040-00001","article-title":"A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding.","volume":"31","author":"Fraser","year":"2008","journal-title":"Drug Saf"},{"key":"R3-21-20210211","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.tem.2004.08.006","article-title":"Prostaglandin receptor signalling and function in human endometrial pathology.","volume":"15","author":"Jabbour","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"R4-21-20210211","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1210\/jc.2006-0724","article-title":"Long-term progestin-only contraceptives result in reduced endometrial blood flow and oxidative stress.","volume":"91","author":"Hickey","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"R5-21-20210211","first-page":"CD000400","article-title":"Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.","author":"Lethaby","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-21-20210211","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2165\/00003495-200363130-00008","article-title":"Tranexamic acid: a review of its use in the management of menorrhagia.","volume":"63","author":"Wellington","year":"2003","journal-title":"Drugs"},{"key":"R7-21-20210211","first-page":"163","article-title":"Role of a non-hormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding.","volume":"36","author":"Gultekin","year":"2009","journal-title":"Clin Exp Obstet Gynecol"},{"key":"R8-21-20210211","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/AOG.0b013e3181f20177","article-title":"Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.","volume":"116","author":"Lukes","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R9-21-20210211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-0528.2008.01926.x","article-title":"The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database.","volume":"116","author":"Sundstrom","year":"2009","journal-title":"BJOG"},{"key":"R10-21-20210211","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/PAS.0b013e318032125e","article-title":"Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas.","volume":"31","author":"Ip","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R11-21-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2516.2007.01611.x","article-title":"Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin.","volume":"14","author":"Rodeghiero","year":"2008","journal-title":"Haemophilia"},{"key":"R12-21-20210211","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.2009.07610.x","article-title":"Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid.","volume":"145","author":"Kouides","year":"2009","journal-title":"Br J Haematol"},{"key":"R13-21-20210211","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.fertnstert.2005.04.062","article-title":"Management of excessive menstrual bleeding in women with hemostatic disorders.","volume":"84","author":"Kadir","year":"2005","journal-title":"Fertil Steril"},{"key":"R14-21-20210211","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2006.03.024","article-title":"Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraception.","volume":"74","author":"Blumenthal","year":"2006","journal-title":"Contraception"},{"key":"R15-21-20210211","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.maturitas.2003.08.002","article-title":"Current treatment of dysfunctional uterine bleeding.","volume":"47","author":"Bongers","year":"2004","journal-title":"Maturitas"},{"key":"R16-21-20210211","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ogc.2008.03.001","article-title":"Management of dysfunctional uterine bleeding.","volume":"35","author":"Casablanca","year":"2008","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R17-21-20210211","first-page":"449","article-title":"How best to manage dysfunctional uterine bleeding.","volume":"59","author":"Maness","year":"2010","journal-title":"J Fam Pract"},{"key":"R18-21-20210211","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.grf.0000159540.11974.17","article-title":"Hormonal management of abnormal uterine bleeding.","volume":"48","author":"Singh","year":"2005","journal-title":"Clin Obstet Gynecol"},{"key":"R19-21-20210211","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1479-828X.1991.tb02769.x","article-title":"Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.","volume":"31","author":"Fraser","year":"1991","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"R20-21-20210211","first-page":"CD000154","article-title":"Oral contraceptive pill for heavy menstrual bleeding.","author":"Farquhar","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-21-20210211","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2006.08.008","article-title":"Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception.","volume":"75","author":"Mishell","year":"2007","journal-title":"Contraception"},{"key":"R22-21-20210211","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/archinte.164.18.1965","article-title":"Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.","volume":"164","author":"Gomes","year":"2004","journal-title":"Arch Intern Med"},{"key":"R23-21-20210211","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"R24-21-20210211","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism.","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"R25-21-20210211","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.contraception.2009.12.009","article-title":"Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.","volume":"81","author":"Dore","year":"2010","journal-title":"Contraception"},{"key":"R26-21-20210211","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0b013e3181beab47","article-title":"Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.","volume":"114","author":"Kaunitz","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R27-21-20210211","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.contraception.2008.11.011","article-title":"Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.","volume":"79","author":"Kaunitz","year":"2009","journal-title":"Contraception"},{"key":"R28-21-20210211","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11916-009-0062-5","article-title":"Hormonal therapies for menstrual migraine.","volume":"13","author":"Calhoun","year":"2009","journal-title":"Curr Pain Headache Rep"},{"key":"R29-21-20210211","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2006.07.005","article-title":"Evaluation of a continuous regimen of levonorgestrel\/ethinyl estradiol: phase 3 study results.","volume":"74","author":"Archer","year":"2006","journal-title":"Contraception"},{"key":"R30-21-20210211","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1210\/jc.2007-2287","article-title":"Effects of continuous versus cyclical oral contraception: a randomized controlled trial.","volume":"93","author":"Legro","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-21-20210211","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00001703-200110000-00006","article-title":"Dysfunctional uterine bleeding: advances in diagnosis and treatment.","volume":"13","author":"Munro","year":"2001","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R32-21-20210211","first-page":"285","article-title":"Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding-a double-blind randomized control study.","volume":"59","author":"DeVore","year":"1982","journal-title":"Obstet Gynecol"},{"issue":"4","key":"R33-21-20210211","first-page":"CD001895","article-title":"Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation.","author":"Hickey","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R34-21-20210211","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cct.2003.08.008","article-title":"Medicine or surgery (Ms): a randomized clinical trial comparing hysterectomy and medical treatment in premenopausal women with abnormal uterine bleeding.","volume":"25","author":"Varner","year":"2004","journal-title":"Control Clin Trials"},{"key":"R35-21-20210211","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/cncr.21058","article-title":"The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system.","volume":"103","author":"Baak","year":"2005","journal-title":"Cancer"},{"key":"R36-21-20210211","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ogc.2007.09.001","article-title":"Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia.","volume":"34","author":"Espindola","year":"2007","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R37-21-20210211","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1479-828X.2009.01093.x","article-title":"Efficacy of micronised vaginal progesterone versus oral dydrogesterone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial.","volume":"49","author":"Karakus","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R38-21-20210211","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1933719108325758","article-title":"Decidualized human endometrial stromal cells mediate hemostasis, angiogenesis, and abnormal uterine bleeding.","volume":"16","author":"Lockwood","year":"2009","journal-title":"Reprod Sci"},{"key":"R39-21-20210211","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00001648-200209000-00015","article-title":"Injectable hormone contraception and bone density: results from a prospective study.","volume":"13","author":"Scholes","year":"2002","journal-title":"Epidemiology"},{"key":"R40-21-20210211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.contraception.2009.02.005","article-title":"Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.","volume":"80","author":"Kaunitz","year":"2009","journal-title":"Contraception"},{"key":"R41-21-20210211","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/00006250-200606000-00055","article-title":"ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions.","volume":"107","author":"ACOG Committee on Practice","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R42-21-20210211","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/AOG.0b013e3181a1d3ce","article-title":"Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis.","volume":"113","author":"Kaunitz","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R43-21-20210211","first-page":"347","article-title":"Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding.","volume":"6","author":"Nelson","year":"2010","journal-title":"Womens Health"},{"key":"R44-21-20210211","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jmig.2009.04.018","article-title":"The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy.","volume":"16","author":"Vilos","year":"2009","journal-title":"J Minim Invasive Gynecol"},{"key":"R45-21-20210211","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ajog.2009.10.863","article-title":"Intrauterine progestins, progesterone antagonists, and receptor modulators: a review of gynecologic applications.","volume":"202","author":"Rodriguez","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"R46-21-20210211","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1471-0528.1990.tb16240.x","article-title":"Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia.","volume":"97","author":"Andersson","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"R47-21-20210211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1074-3804(00)80005-5","article-title":"Abnormal uterine bleeding in the reproductive years. Part II-medical management.","volume":"7","author":"Munro","year":"2000","journal-title":"J Am Assoc Gynecol Laparosc"},{"key":"R48-21-20210211","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1469-0705.2002.00805.x","article-title":"Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy.","volume":"20","author":"Inki","year":"2002","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R49-21-20210211","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.contraception.2009.09.012","article-title":"A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding.","volume":"81","author":"de Souza","year":"2010","journal-title":"Contraception"},{"key":"R50-21-20210211","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(00)03615-1","article-title":"Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial.","volume":"357","author":"Hurskainen","year":"2001","journal-title":"Lancet"},{"key":"R51-21-20210211","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.291.12.1456","article-title":"Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up.","volume":"291","author":"Hurskainen","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"R52-21-20210211","first-page":"CD001017","article-title":"Danazol for heavy menstrual bleeding.","author":"Beaumont","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R53-21-20210211","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.fertnstert.2008.08.017","article-title":"Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age.","volume":"92","author":"Luisi","year":"2009","journal-title":"Fertil Steril"},{"key":"R54-21-20210211","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijgo.2008.10.032","article-title":"Gonadotropin-releasing hormone analog combined with a low-dose oral contraceptive to treat heavy menstrual bleeding.","volume":"104","author":"Cetin","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"R55-21-20210211","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/01.ogx.0000259228.70277.6f","article-title":"Medical therapies for chronic menorrhagia.","volume":"62","author":"Nelson","year":"2007","journal-title":"Obstet Gynecol Surv"},{"issue":"2","key":"R56-21-20210211","first-page":"000547","article-title":"Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.","author":"Lethaby","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-21-20210211","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0015-0282(00)00694-4","article-title":"Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri.","volume":"74","author":"Scialli","year":"2000","journal-title":"Fertil Steril"},{"key":"R58-21-20210211","first-page":"396","article-title":"Current management of endometrial hyperplasia and endometrial intraepithelial neoplasia (EIN).","volume":"30","author":"Gultekin","year":"2009","journal-title":"Eur J Gynaecol Oncol"},{"key":"R59-21-20210211","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.2009.24.1315","article-title":"Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.","volume":"28","author":"Lacey","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042192-201104000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:34:04Z","timestamp":1618277644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201104000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e318212499c","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}